Amarin Appoints New CMO, CDO; AGM Resolutions Passed
Ticker: AMRN · Form: 8-K · Filed: Apr 22, 2024 · CIK: 897448
| Field | Detail |
|---|---|
| Company | Amarin Corp PLC\UK (AMRN) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, agm, corporate-governance
Related Tickers: AMRN
TL;DR
Amarin beefs up exec team with new CMO/CDO, shareholders give nod to board.
AI Summary
On April 18, 2024, Amarin Corporation plc announced the appointment of Dr. Karim Mikhail as Chief Medical Officer and Dr. Patrick O'Sullivan as Chief Development Officer. The company also reported on the successful completion of its annual general meeting, where shareholders approved all proposed resolutions, including the re-election of directors and the appointment of auditors.
Why It Matters
The appointment of key medical and development officers signals a strategic shift or reinforcement in Amarin's leadership, potentially impacting its drug development pipeline and regulatory strategies. The successful AGM indicates shareholder confidence and smooth corporate governance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and executive appointments, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Amarin Corporation plc (company) — Registrant
- Dr. Karim Mikhail (person) — Appointed Chief Medical Officer
- Dr. Patrick O'Sullivan (person) — Appointed Chief Development Officer
- April 18, 2024 (date) — Date of earliest event reported
FAQ
Who were the key individuals appointed to new executive roles?
Dr. Karim Mikhail was appointed Chief Medical Officer and Dr. Patrick O'Sullivan was appointed Chief Development Officer.
What was the date of the earliest event reported in this 8-K?
The date of the earliest event reported is April 18, 2024.
What significant corporate event was completed by Amarin?
Amarin completed its annual general meeting (AGM).
Were all resolutions proposed at the AGM approved by shareholders?
Yes, all proposed resolutions, including the re-election of directors and the appointment of auditors, were approved by shareholders.
What is Amarin Corporation plc's jurisdiction of incorporation?
Amarin Corporation plc is incorporated in England and Wales.
Filing Stats: 1,428 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2024-04-22 12:54:42
Filing Documents
- amrn-20240418.htm (8-K) — 103KB
- amrn-ex3_1.htm (EX-3.1) — 328KB
- amrn-ex10_2.htm (EX-10.2) — 6KB
- amrn-ex99_1.htm (EX-99.1) — 20KB
- img114078973_0.jpg (GRAPHIC) — 39KB
- 0000950170-24-046290.txt ( ) — 710KB
- amrn-20240418.xsd (EX-101.SCH) — 33KB
- amrn-20240418_htm.xml (XML) — 5KB
02. Compensatory Arrangements of Certain Officers
Item 5.02. Compensatory Arrangements of Certain Officers. As described under Item 5.07 of this Current Report on Form 8-K, on April 18, 2024, at the Annual General Meeting of Shareholders (the " Annual Meeting ") of Amarin Corporation plc (the " Company "), the Company's shareholders approved Amendment No. 3 to the Company's 2020 Stock Incentive Plan, as amended (the " 2020 Plan ") to increase the share reserve under the 2020 Plan by 10,000,000 ordinary shares or ADSs (as defined below), as the case may be (the " Shares ") and to increase the number of Shares that may be issued in the form of incentive stock options by 10,000,000 Shares (the " Plan Amendment No. 3 "). The 2020 Plan was originally adopted by the Company's board of directors on March 16, 2020 and approved by the Company's shareholders at its 2020 annual general meeting. The Company's officers and directors are among the persons eligible to receive awards under the 2020 Plan in accordance with the terms and conditions thereunder. A detailed summary of the 2020 Plan and the Plan Amendment No. 3 is set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the " SEC ") on March 4, 2024 (the " Proxy Statement " under the caption " Proposal No. 6: Adoption of an Amendment to the Company's 2020 Stock Incentive Plan , As Amended " which summary is incorporated herein by reference). That detailed summary of the 2020 Plan and the Plan Amendment No. 3, and the foregoing description of the Plan Amendment No. 3, are qualified in their entirety by reference to the full text of the 2020 Plan and the Plan Amendment No. 3, a copy of each of which is filed herewith as Exhibit 10.1 and 10.2, respectively, and which are incorporated herein by reference.
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held the Annual Meeting on April 18, 2024. The matters set forth below were voted on and approved by the Company's shareholders at the Annual Meeting. There were approximately 421,174,494 ordinary shares entitled to vote at the Annual Meeting based on the February 20, 2024 record date, of which approximately 401,870,067 were held in the name of Citibank, N.A., which issues Company-sponsored American Depositary Receipts ("ADRs") evidencing American Depositary Shares ("ADSs") which, in turn, each represent one ordinary share. Of the ordinary shares entitled to vote, 255,152,802 shares, or approximately 61%, were present and voting in person or by proxy at the Annual Meeting. In accordance with the Company's Articles of Association, the presence, in person or by proxy, of a quorum for the transaction of business at the Annual Meeting was constituted by at least two shareholders who held shares as of February 20, 2024. The matters set forth below were voted on at the Annual Meeting. Detailed descriptions of these matters and voting procedures applicable to these matters at the Annual Meeting are contained in the Proxy Statement. All matters were approved in accordance with the Company's Articles of Association. Set forth below are the voting results for each matter. (1) An ordinary resolution to re-elect Mr. Patrick Holt as a director: Votes For Votes Against Abstentions Broker Non- Votes 136,073,314 5,215,323 2,477,170 111,386,995 (2) An ordinary resolution to re-elect Mr. Louis Sterling III as a director: Votes For Votes Against Abstentions Broker Non- Votes 131,897,029 9,379,465 2,489,313 111,386,995 (3) An ordinary resolution to re-elect Ms. Patrice Bonfiglio as a director: Votes For Votes Against Abstentions Broker Non- Votes 132,861,738 8,367,933 2,536,136 111,386,995 (4) A non-binding advisory vote to approve the compensati
01. Other Events
Item 8.01. Other Events. On April 22, 2024, the Company issued a press release titled "Amarin Announces Results of Annual General Meeting of Shareholders." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Articles of Association of the Company 10.1 The Amarin Corporation plc 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Commission on July 14, 2020) 10.2 Amendment No. 3 to the Amarin Corporation plc 2020 Stock Incentive Plan 99.1 Press Release, dated April 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 22, 2024 Amarin Corporation plc By: /s/ Jonathan Provoost Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary